Methotrexate Sodium Patent Expiration
Methotrexate Sodium is Used for treating acute lymphoblastic leukemia and juvenile rheumatoid arthritis. It was first introduced by Strides Pharma Global Pte Ltd
Methotrexate Sodium Patents
Given below is the list of patents protecting Methotrexate Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xatmep | US10231927 | Methotrexate composition | Jan 02, 2033 | Azurity |
| Xatmep | US10610485 | Methotrexate composition | Jan 02, 2033 | Azurity |
| Xatmep | US11116724 | Methotrexate composition | Jan 02, 2033 | Azurity |
| Xatmep | US11969503 | Methotrexate composition | Jan 02, 2033 | Azurity |
| Xatmep | US9259427 | Methotrexate composition | Jan 02, 2033 | Azurity |
| Xatmep | US9855215 | Methotrexate composition | Jan 02, 2033 | Azurity |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Methotrexate Sodium's patents.
Latest Legal Activities on Methotrexate Sodium's Patents
Given below is the list recent legal activities going on the following patents of Methotrexate Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Sep, 2023 | US10610485 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Aug, 2022 | US10231927 |
| Patent Issue Date Used in PTA Calculation Critical
| 14 Sep, 2021 | US11116724 |
| Recordation of Patent Grant Mailed Critical
| 14 Sep, 2021 | US11116724 |
| Email Notification Critical
| 26 Aug, 2021 | US11116724 |
| Issue Notification Mailed Critical
| 25 Aug, 2021 | US11116724 |
| Dispatch to FDC | 16 Aug, 2021 | US11116724 |
| Application Is Considered Ready for Issue Critical
| 16 Aug, 2021 | US11116724 |
| Issue Fee Payment Received Critical
| 10 Aug, 2021 | US11116724 |
| Issue Fee Payment Verified Critical
| 10 Aug, 2021 | US11116724 |
Methotrexate Sodium's Family Patents
